EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 168 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $455,359 | +47984.4% | 28,875 | -10.8% | 0.01% | -73.7% |
| Q4 2022 | $947 | -99.9% | 32,382 | +17.9% | 0.02% | +18.8% |
| Q3 2022 | $726,000 | -28.3% | 27,461 | +20.5% | 0.02% | -40.7% |
| Q2 2022 | $1,013,000 | +127.1% | 22,793 | +207.0% | 0.03% | +35.0% |
| Q4 2019 | $446,000 | -62.0% | 7,425 | -64.3% | 0.02% | -50.0% |
| Q3 2019 | $1,175,000 | +113.2% | 20,778 | +109.8% | 0.04% | +150.0% |
| Q2 2019 | $551,000 | -8.0% | 9,903 | -16.6% | 0.02% | -36.0% |
| Q1 2019 | $599,000 | -30.0% | 11,870 | -44.1% | 0.02% | +47.1% |
| Q4 2018 | $856,000 | -1.8% | 21,244 | +68.9% | 0.02% | -22.7% |
| Q3 2018 | $872,000 | +185.9% | 12,577 | +211.9% | 0.02% | +100.0% |
| Q2 2018 | $305,000 | +12.1% | 4,033 | -42.4% | 0.01% | +83.3% |
| Q2 2016 | $272,000 | +24.2% | 7,000 | +29.6% | 0.01% | 0.0% |
| Q1 2016 | $219,000 | -61.8% | 5,400 | -16.5% | 0.01% | -62.5% |
| Q4 2015 | $573,000 | – | 6,467 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |